Skip to content

Epirubicin for the Treatment of Sepsis & Septic Shock

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515776-12-00
Acronym
EPOS_ZKSJ0134
Enrollment
45
Registered
2024-10-01
Start date
2022-06-30
Completion date
2025-05-21
Last updated
2024-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with sepsis or septic shock, currently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.

Brief summary

Safety as assessed by myelotoxicity until day 14 is the primary endpoint.

Detailed description

Degree of organ dysfunction measured by SOFA score., Occurrence of Adverse Events., Occurrence of Cardiotoxicity., Survival at day 14, 28 and 90., SOFA “Success” rate defined as a decrease of procalcitonin (PCT) serum concentration by 80% or more of its intra-individual peak value or to 0.5 μg/L or lower within 72 hours after randomization.

Interventions

DRUGEpirubicin 50 mg HEXAL® Injektionslösung

Sponsors

Friedrich-Schiller-Universitaet Jena, Friedrich-Schiller-Universitaet Jena
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Safety as assessed by myelotoxicity until day 14 is the primary endpoint.

Secondary

MeasureTime frame
Degree of organ dysfunction measured by SOFA score., Occurrence of Adverse Events., Occurrence of Cardiotoxicity., Survival at day 14, 28 and 90., SOFA “Success” rate defined as a decrease of procalcitonin (PCT) serum concentration by 80% or more of its intra-individual peak value or to 0.5 μg/L or lower within 72 hours after randomization.

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026